Fennec Pharmaceuticals (FENC) Stock: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$10.08
-0.24 (-2.33%)
▼
5d:
+1.0%
30d:
-5.08%
90d:
-1.27%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: FENC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: FENC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$19.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.38
18.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $10.08, which is considered oversold relative to its 30-day fair value range of $10.23 to $10.77. The stock's valuation (Forward PE: 10.6) is in line with its historical norms (10.8). Remarkably, the market is currently pricing in an annual earnings decline of 0.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, FENC is in a uptrend. The price is currently testing key support at $9.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FENC scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.67 (+75.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FENC is in a uptrend. The price is currently testing key support at $9.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FENC scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.67 (+75.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.23 -
$10.77
Company Quality Score
48/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 16th percentile)
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 75.3% below Wall St target ($17.67)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.23 -
$10.77
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.50
(14.8%)
Support & Resistance Levels
Support Level
$9.87
Resistance Level
$10.86
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.63
Wall Street Target
$17.67
(+75.3%)
Revenue Growth (YoY)
85.2%
Profit Margin
-5.5%
Valuation Discount vs History
-0.6% cheaper
PE vs Historical
10.6 vs 10.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.6%
(market-implied from PE analysis)
1-Year Target
$10.02
(-1%)
2-Year Target
$9.96
(-1%)
3-Year Target
$9.90
(-2%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
$10.06
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 194.4%)
$63.54
(+530%)
Base:
(SPY PE: 10.6, Growth: 194.4%)
$34.02
(+238%)
Bear:
(PE: 9.0, Growth: 194.4%)
$28.92
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 10.8
Stabilization Target:
$10.24
(+1.6%)
PE Expansion Potential:
+1.6%
Share & Embed Analysis
Last updated: October 24, 2026 12:03 AM ET
Data refreshes hourly during market hours. Next update: 1:03 AM
Data refreshes hourly during market hours. Next update: 1:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
